They were the impetus for investor euphoria Phase 3 results in second-line treatment of gastrointestinal stromal tumors (GIST). Cogent therapy combines bezuclastinib with sunitinib and extends the median progression-free survival (PFS) to 16.5 months versus 9.2 months for sunitinib alone. Importantly, the resulting regimen was assessed as well tolerated.
PFS, that is progression-free survivalis the period in which the patient lives with the disease, but its deterioration is not observed — this is one of the most frequently used criteria for the effectiveness of new oncology drugs. It is in this field that the bezuclastinib + sunitinib combination showed an advantage over the comparator standard.
Special offer
The therapy is intended for patients with GIST who are resistant to imatinib, a commonly used first-line oral drug. According to the company, it is the first positive phase 3 trial in this second-line population in over 20 yearswhich highlights the importance of the announced results and the potential to significantly change the therapeutic landscape of GIST.
The next part below the video:
Investors reacted immediately
At the market level, the reaction was immediate. Cogent's capitalization soared with the publication of the announcement, and a investors began to discount the scenario of further development of the program and possible regulatory steps. Although the broad market indices were rising, the scale of the movement on COGT clearly distinguished the company from the entire stock exchange.
What are the conclusions? A combination of a solid clinical effect, i.e. a significantly longer PFS, with declared good tolerance builds a credible narrative about the therapeutic value of the PEAK project. If the trend is confirmed by further analyzes and actions by regulators, Cogent may gain a position in second-line GIST treatment regimens, where there have been no breakthroughs for decades.
The company's shares have increased by as much as 336% since the beginning of the year.
Note: the companies and valuations included in the text are for information purposes only and do not constitute a recommendation or any other form of suggestion for the purchase or sale of financial products. Investment decisions should be preceded by your own analysis of risk and financial situation.
